FDA Grants Second Approval Under the National Priority Voucher Pilot Program

26 Feb 20264 min read0 views

GIST

The U.S. Food and Drug Administration today issued an approval for the lung cancer drug Hernexeos (zongertinib) as a part of the new Commissioner's National Priority Voucher (CNPV) pilot program.

The application was filed on January 13, 2026. In the clinical trial data submitted to the agency, a remarkable 76% of previously untreated patients had a substantial decrease in tumor size, representing a significant improvement from the current standard of care whereby 30-45% of patients are typically expected to demonstrate this response.

“As a part of the national priority voucher program, the FDA is on the hunt for game-changing therapies that can qualify for a priority review. In this case a final decision was rendered 44 days after the filing date,” said FDA Commissioner Marty Makary, M.D., M.P.H.

Clinical Editorial

Strategic context and programmatic framework

Selected entities receive a voucher that enhances communications and supports rolling and shortened reviews.

The FDA issued approval for Hernexeos (zongertinib) under the Commissioner's National Priority Voucher (CNPV) pilot program, marking a second approval within this initiative.
The company filing date for the submission was January 13, 2026, and the agency highlighted rapid turnaround under the pilot, noting a final decision occurred 44 days after filing.
The CNPV program aims to hasten approvals for therapies addressing critical national health priorities, including large unmet medical needs and potential benefits such as domestic manufacturing and affordability.

Therapeutic indication and patient population

Hernexeos is indicated for adults with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors harbor activating mutations in the HER2 (ERBB2) tyrosine kinase domain, as detected by an FDA-authorized diagnostic test.
The current approval expands access to patients who have not previously received systemic therapy, following an accelerated approval granted in August 2025 for adults with non-squamous NSCLC with the same mutation who had prior systemic therapy.

Evidence base and signal strength

The clinical data submitted to the FDA demonstrated a substantial tumor size reduction in 76% of previously untreated patients with the targeted HER2 mutation subset.
This response rate is contrasted with a referenced baseline response expectation under standard care of 30-45% for similar populations, indicating a notable improvement within the trial context reported by the agency.
The briefing emphasizes that these observations originate from the sponsor’s clinical trial data provided to the FDA as part of the approval package.

Safety profile and adverse events

Serious adverse effects linked to Hernexeos include hepatotoxicity, left ventricular dysfunction, interstitial lung disease/pneumonitis, and embryofetal toxicity.
The most common adverse events reported are diarrhea, rash, hepatotoxicity, fatigue, nausea, musculoskeletal pain, and upper respiratory tract infection.
The summary text does not quantify the incidence rates of these events, nor does it provide detail on management strategies; it only enumerates the toxicity spectrum observed in the regulatory materials.

Regulatory status and process specifics

The accelerated approval pathway first applied in August 2025 and has now been extended to treatment-naïve patients with the same molecular profile, representing a broader indication.
The Commissioner's remarks frame the decision as part of an expedited regulatory process designed to deliver promising therapies more rapidly while maintaining safety guardrails.
The FDA’s statement situates this action within the broader mission to ensure the safety, effectiveness, and security of medical products and to support public health objectives.

Clinical context and limitations of reporting

The article notes the burden of lung cancer in the United States, citing National Cancer Institute estimates for incident cases and mortality in 2025, to contextualize the potential impact of rapid approval for this molecularly targeted therapy.
Limitations of the source material include a lack of numeric detail on the trial design (e.g., sample size, randomization, comparator arms), absence of precise confidence intervals or p-values, and no long-term outcome data beyond the reported tumor response signal.
It is explicitly stated that the content summarizes agency-reported data and does not incorporate external corroboration beyond the FDA release provided.